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,Q  D QDWLRQDO KXPDQ SDSLOORPDYLUXV +39 LPPX-
QL]DWLRQ SURJUDP XVLQJ D ELYDOHQW YDFFLQH DJDLQVW +39
W\SHVDQGZDVLPSOHPHQWHGLQ6FRWODQGDORQJZLWK




OLTXLGEDVHG F\WRORJ\ VDPSOHV IURP ZRPHQ XQGHUJRLQJ
WKHLU ¿UVW FHUYLFDO VFUHHQLQJ WHVW IRU SUHFDQFHURXV FHUYL-
cal disease. By linking vaccination, cervical screening, and 
+39WHVWLQJGDWDRYHU WKHVWXG\SHULRG ZHIRXQGDGH-
FOLQHLQ+39W\SHVDQGVLJQL¿FDQWGHFUHDVHVLQ+39
types 31, 33, and 45 (suggesting cross-protection), and 
D QRQVLJQL¿FDQW LQFUHDVH LQ +39  ,Q DGGLWLRQ DPRQJ
QRQYDFFLQDWHG ZRPHQ +39 W\SHV  DQG  LQIHFWLRQV
ZHUHVLJQL¿FDQWO\ORZHULQWKDQLQ2XUUHVXOWV
preliminarily indicate herd immunity and sustained effec-
tiveness of the bivalent vaccine on virologic outcomes at 
the population level.
HXPDQ SDSLOORPDYLUXV +39 YDFFLQDWLRQ SURJUDPVare established in several countries worldwide (13). 




of age (3-year catch-up cohort) were offered the vaccine 
from September 2008 through August 2011. Starting in 
September 2012, the licensed quadrivalent vaccine re-
SODFHGWKHELYDOHQWYDFFLQHLQWKHSURJUDP&RQVHTXHQWO\
GDWDLQWKLVDUWLFOHUHÀHFWWKHHIIHFWVRIWKHELYDOHQWYDF-
cine only. Since the 200809 school year, receipt of all 3 
GRVHVZDV!IRUJLUOVLQWKHURXWLQHFRKRUWDQGGXULQJ







precancerous disease from 2009 through 2012 (5). These 
data reconcile with studies undertaken in other settings. In 
(QJODQGDQHFRORJLFVWXG\VKRZHGWKDWDQG
RIYDJLQDOVZDEVDPSOHVZHUHSRVLWLYHIRU+39DQG
in the pre- and postvaccination periods, respectively (6). 
Markowitz et al. also demonstrated that despite low vac-
FLQH FRYHUDJH +39  DQG  SUHYDOHQFH DPRQJ JLUOV
who had received the quadrivalent vaccine in the routine 
DQGFDWFKXSSURJUDPVZDVUHGXFHGE\7). Evidence 
LVDOVRHPHUJLQJZLWKUHJDUGWR WKHHIIHFWLYHQHVVRI+39
vaccination for reducing the incidence and prevalence of 
low- and high-grade precancerous cervical lesions (811). 
In Australia, recent studies designed to assess the extent of 
KHUGLPPXQLW\WRYDFFLQHW\SH+39KDYHVKRZQHYLGHQFH
for potential development of herd immunity in the nonvac-
cinated population (12,13). However, few studies of the 
extent of herd immunity have been published, particularly 
studies in which vaccination status can be directly linked to 
viral outcomes.
The ability to directly link large datasets (including 
cervical screening, vaccination, and disease registers) in 
6FRWODQG WKURXJK D XQLTXH SHUVRQDO LGHQWL¿HU WKH &RP-
PXQLW\+HDOWK,QGH[&+,HQDEOHVXVWRFRPSUHKHQVLYH-
ly assess the effects of vaccination, including the extent 
RI SRWHQWLDO KHUG LPPXQLW\ %\ LQFOXGLQJ VDPSOHV IURP
ZRPHQ XQGHUJRLQJ WKHLU ¿UVW FHUYLFDO VPHDU WHVWLQJ LQ
ZHIXUWKHUDVVHVVHGWKHHIIHFWVRI+39YDFFLQDWLRQ
among young women in Scotland by comparing prevalence 
RI+39DQG+39DQGDQGRWKHUKLJK
ULVN +39 W\SHV DPRQJ ZRPHQ ZKR ZHUH IXOO\ YDFFLQDW-
ed as part of the catch-up cohort with prevalence among 
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nonvaccinated women in the same birth cohorts. Addition-
ally, we investigated whether the prevalence of any nonvac-
FLQH+39W\SHVZDVJUHDWHUDPRQJYDFFLQDWHGZRPHQ8V-
ing these updated data, we determined whether high uptake 
of the vaccine protects nonvaccinated women by assessing 
the trend, over birth cohort, for the proportion of nonvacci-
QDWHGZRPHQZLWKSRVLWLYHUHVXOWVIRUHDFK+39RXWFRPH
Materials and Methods
Surveillance Program and Sample Population
7KH 6FRWWLVK &HUYLFDO 6FUHHQLQJ 3URJUDPPH LV DQ RUJD-
nized, national, callrecall program that invites women 
±\HDUVRIDJHWRYLVLWWKHLUJHQHUDOSUDFWLWLRQHUIRUD
cervical smear test (14). The program is facilitated through 
WKH HOHFWURQLF 6FRWWLVK &\WRORJ\ &DOO±5HFDOO 6\VWHP
which records which women are eligible for screening and 
contains information about cytology, histology, vaccina-
tion status, recall, and management.
During 20092013, the National Health Service cyto-
SDWKRORJ\ODERUDWRULHVWKDWVHUYHWKH6FUHHQLQJ3URJUDPPH
collected |1,000 liquid-based cytology samples per year 
from women 2021 years of age who were undergoing 
WKHLU¿UVWFHUYLFDOVPHDUWHVWLQJ$OOVDPSOHVFROOHFWHGGXU-
LQJ±ZHUHVXEMHFWHGWR+39JHQRW\SLQJDQGWKH
results from the 20092010 samples constituted a prevac-
cination baseline. The sampling methods used in this study 
are described elsewhere (5).
Data and Linkage
Liquid-based cytology samples collected by the cytol-




Information Services Division of the Scottish National 




patients residence was used to rank the geographic data 
zone for each sample according to the Scottish Index of 




A detailed account of the testing procedures has been de-
scribed elsewhere (5,QEULHI+39JHQRW\SLQJZDVSHU-
IRUPHG E\ XVLQJ WKH 0XOWLPHWUL[ +39 *HQRW\SLQJ .LW
'LDPH[+HLGHOEHUJ*HUPDQ\ZKLFKFDQGHWHFW+39




DFFRUGLQJWR WKH ODWHVW ,QWHUQDWLRQDO$JHQF\IRU5HVHDUFK
RQ&DQFHUJURXSLQJV157KLVDVVD\FDQDOVRGHWHFWORZ
ULVN+39W\SHV+39DQG,QWHUQDWLRQDO




3RZHUFDOFXODWLRQV IRU WKH OLTXLGEDVHGF\WRORJ\VDPSOHV




3 doses of the vaccine and those who received none. The 
%RQIHUURQLFRUUHFWLRQVLJQL¿FDQFHOHYHOĮ ZDV
used because of the multiple statistical testing conducted 
IRU WKH  QRQYDFFLQH +39 W\SHV GHWHFWHG E\ WKH DVVD\
6LJQL¿FDQFH ZDV DVVHVVHG DW Į    IRU +39 W\SHV 
and 18. Association between the number of doses of vac-
FLQH UHFHLYHG DQG +39 RXWFRPH ZDV PHDVXUHG E\ XVLQJ
logistic regression adjusted for deprivation score, birth co-
hort year, and age at vaccination. A linear trend test was 







evaluated by using logistic regression and testing for a lin-
HDUWUHQGRYHUWLPHLQWKHSUHYDOHQFHRI+39DQGWKH





:H DQDO\]HG  OLTXLGEDVHG F\WRORJ\ VDPSOHV IURP
ZRPHQ±\HDUVRIDJHZKRXQGHUZHQWWKHLU¿UVWFHU-
vical smear testing during 20092013. The number of 
samples received each year was distributed evenly between 
the quintiles of the Scottish Index of Multiple Deprivation 
(|VDPSOHVTXLQWLOH7DEOH2YHUDOOYDOLG+39WHVW
UHVXOWVZHUHDYDLODEOHIRUVDPSOHVRIZKLFK










and 2010 were from women who were not eligible for the 
FDWFKXSFDPSDLJQWKHUHIRUHDQGRIWKHVDPSOHV
from these years, respectively, came from nonvaccinated 
women (Figure). 
Effect on Vaccine-Type Infections









 &, ± RI WKH VDPSOHV FROOHFWHG LQ 
were positive (5).
8QDGMXVWHGDQDO\VLVVKRZHGDVLJQL¿FDQWOLQHDUWUHQG
IRUELUWK FRKRUW DQGQXPEHURIGRVHV DZRPDQ UHFHLYHG
SUHYDOHQFH RI +39  DQG  ZDV ORZHU DPRQJ ZRPHQ
from later birth cohorts and women who had received more 





Table 1. <HDUO\GLVWULEXWLRQRIOLTXLG-based cytology samples collected IURPZRPHQ±21 years of age undergoing their first 
cervical smear collection, Scotland, 2009±2013* 
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tempered for birth cohort (Table 3). The adjusted odds ratio 
25RIEHLQJLQIHFWHGZLWK+39RUGHFUHDVHGZLWK
HYHU\GRVH)RUGRVH25ZDV&,±
 GRVHV 25   &, ± DQG  GRVHV 25
&,±:RPHQIURPOHDVWGHSULYHGDU-
HDV ZHUH VLJQL¿FDQWO\ OHVV OLNHO\ WR KDYH SRVLWLYH UHVXOWV
IRU+39DQG WKDQZHUH WKRVH IURPPRUHGHSULYHG
DUHDVS 7KHOLQHDUWUHQGIRUDJHDWYDFFLQDWLRQ
ZDVVLJQL¿FDQWRGGVRILQIHFWLRQZLWK+39DQGZHUH
greater for women vaccinated at older ages than for those 
YDFFLQDWHGDW±\HDUVRIDJHS7DEOH
Evidence for Cross-Protection
3UHYDOHQFH RI +39 W\SHV   DQG  GHFUHDVHG
among vaccinated compared with nonvaccinated women 
SS DQGSUHVSHFWLYHO\)LJ-
XUH 7KH SRVLWLYLW\ IRU FURVVSURWHFWLYH +39 W\SHV ZDV
  &, ± DPRQJ QRQYDFFLQDWHG
ZRPHQDQG&,±DPRQJIXOO\YDFFL-
nated women (Table 2). During 20092013, overall cross-
SURWHFWLYHW\SHSUHYDOHQFHDOVRGHFOLQHGIURP
&, ± LQ  WR   &, ± LQ
2013 (5).
According to unadjusted analyses, the odds of being 
LQIHFWHGZLWKFURVVSURWHFWLYHW\SHVGHFUHDVHGVLJQL¿FDQWO\
DFFRUGLQJ WRELUWK FRKRUW\HDU S EXW DGMXVWHG
DQDO\VHV VKRZHG QR VXFK VLJQL¿FDQW HIIHFW S   
because of confounding of the effect with vaccination 
VWDWXV7DEOHV$VWURQJVLJQL¿FDQW OLQHDU WUHQGZDV
REVHUYHG DFFRUGLQJ WR WKHQXPEHURIGRVHV UHFHLYHG WKH
adjusted odds of positivity decreased with the number of 
GRVHV UHFHLYHG GRVH 25  > &, ±@ YV
GRVH25>&,±@S2GGVRI
SRVLWLYLW\IRUFURVVSURWHFWLYH W\SHVZHUHVLJQL¿FDQWO\UH-
duced among women from the least deprived backgrounds 
S  KRZHYHU QR VLJQL¿FDQWGLIIHUHQFHZDVRE-
VHUYHGDFFRUGLQJWRDJHDWYDFFLQDWLRQS 
Positivity for High-Risk HPV Types other than  
16, 18, 31, 33, and 45
The overall prevalence of nonvaccine, noncross-protec-
WLYH KLJKULVN +39 W\SHV +39      
DQGVLJQL¿FDQWO\LQFUHDVHGIURP&,
±LQWR&,





+39  ZDV PDUJLQDOO\ DQG QRQVLJQL¿FDQWO\ LQFUHDVHG








Table 2. 3UHYDOHQFHDQGXQDGMXVWHGRGGVRIpositivity for +39types 16 or 18 and cross-protective types stratified by year of sample 







(95% CI) 1RSRV 3RV&, 
Unadjusted 25
(95% CI) 
Collection year         
 2009 1,652  31.0) 1 (reference)  215 13.0 (11.5 1 (reference) 
 2010 1,053 333 31.6 (28.934.5) 1.35)  143 13.6 (11.615.8) 1.05 (0.841.32) 
 2011 1,001 233 26.0) 0.90)  104 12.4)  (0.600.99) 
 2012 993 169 19.5) 0.51 (0.420.62)  83 8.4 (6.810.2) 0.61  
 2013 1,016 103 10.1 (8.4012.2) 0.28 (0.220.35)  64 6.3 (5.08.0) 0.45 (0.330.60) 
1RGRVHVYDFFLQHUHFHLYHG       
 0 3,619 1062 30.9) 1 (reference)  468 12.9 (11.914.1) 1 (reference) 
 1 89 20 22.5 (15.032.2) 1.13)  15 16.9 (10.526.0)  2.33) 
 2 154 28 18.2 (12.925.0) 0.54 (0.350.80)  11 12.3) 0.52 (0.260.92) 
 3 1,853 204 012.5) 0.30 (0.250.35)  115 6.2 (5.2 0.45 (0.360.55) 
Birth year         
 1988 844 251 32.9) 1 (reference)  119 14.1 (11.916.6) 1 (reference) 
 1989 1,196 343 (26.231.3)   140  0.82 (0.631.06) 
 1990 1,204 349 29.0 (26.531.6) 1.18)  155 12.9 (11.114.9) 0.91  
 1991   23.0) 0.60 (0.48  80 11.3) 0.62 (0.460.83) 
 1992 1,261 169 13.4 (11.615.4) 0.36 (0.290.45)  90   (0.350.62) 
 1993 393  6.90 (4.89.8) 0.26)  25 6.4 (4.39.2) 0.41 (0.260.63) 
Age at vaccination, y        
 1516   9.6) 1 (reference)  52 5.4 (4.1.0) 1 (reference) 
  631  12.5 (10.215.3) 0 (1.222.38)   9.8) 1.42 (0.942.13) 
 18 391 65 16.6 (13.320.6) 3.40)  30   (0.912.32) 
 >18 109 33 30.3 (22.439.5) 5.31 (3.288.48)  12 11 (6.418.3) 2.23 (1.14.18) 
+39KXPDQSDSLOORPDYLUXV25RGGVUDWLRSRVSRVLWLYH 
+39W\SHVRU 




   7DEOH  $FFRUGLQJ WR DGMXVWHG DQDO\VLV WKH
odds of positivity for a nonvaccine, noncross-protective, 
KLJKULVN+39W\SHZDVWLPHVKLJKHUIRUWKRVHERUQLQ
1992 and 1993 than for those born in 1988 (reference birth 
cohort). Although the unadjusted analysis shows some 
tempering of this effect, a linear trend was still present (p 
 7DEOH:KHQDGMXVWHGIRUELUWKFRKRUWRGGVRI
infection were slightly reduced for women who received 
3 doses of vaccine compared with women who received 
QR YDFFLQH EXW WKLV GLIIHUHQFH ZDV QRW VLJQL¿FDQW S  
1RVLJQL¿FDQWOLQHDUWUHQGZDVIRXQGIRUQRQYDF-
FLQH QRQ±FURVVSURWHFWLYH KLJKULVN+39 W\SHSRVLWLYLW\
DFFRUGLQJWRGHSULYDWLRQVWDWXVS RUDJHDWYDF-
FLQDWLRQS 
Overall Positivity for any HPV Type
3UHYDOHQFHRIDOO+39W\SHVGHWHFWHGE\WKHDVVD\UH-
PDLQHG XQFKDQJHG IURP  WR   > &,
±@LQDQG>&,±@
LQEXWGHFUHDVHGWR&,±
in 2013 (Table 4) (52YHUDOO+39SRVLWLYLW\ZDV







According to adjusted analyses, however, this trend was 
QRWVLJQL¿FDQWS 7DEOHV+39LQIHFWLRQZDV
VLJQL¿FDQWO\ OHVV OLNHO\ DPRQJZRPHQZKRKDG UHFHLYHG
3 doses of vaccine than among those who had received no 
doses (p<0.004) and was also less likely among women 





Prevalence of HPV among Nonvaccinated Women 
(Herd Immunity)
3UHYDOHQFH RI +39  DQG  DPRQJ QRQYDFFLQDWHG
women remained relatively stable at |GXULQJ±
EXWGHFUHDVHG WRLQ 7DEOH'XULQJ
± SUHYDOHQFH RI +39 W\SHV   RU  GH-
FOLQHGJUDGXDOO\IURPLQWRLQ,Q
WKHRGGVRILQIHFWLRQZLWK+39W\SHVDQGZDV
UHGXFHG DPRQJ QRQYDFFLQDWHG ZRPHQ 25  >
&,±@FRPSDUHGZLWKWKHEDVHOLQHRGGVLQ
and testing for trend over all years showed a marginal de-
FUHDVHRYHUWLPHS 7DEOH2GGVRILQIHFWLRQ
ZLWK+39W\SHVRUZHUHUHGXFHGLQDQG
2013 compared with 2009, but these odds were not sig-
QL¿FDQW DQGQRVLJQL¿FDQW OLQHDU WUHQGZDVREVHUYHG S





Table 3. Adjusted odds of positivity for +39RUDQGFURVV-protective +39types by birth year, number of doses of vaccine 





$GMXVWHG25&, /LQHDUWUHQGSYDOXH $GMXVWHG25&, /LQHDUWUHQGSYDOXH 
Birth year  0.0005   0.2413 
 1988 1 (reference)   1 (reference)  
 1989    0.82 (0.631.06)  
 1990 1.02 (0.841.24)     
 1991 1.25)   0.86 (0.601.21)  
 1992 0.84 (0.631.11)   1.12)  
 1993 0.43 (0.26   1.20)  
1RGRVHVYDFFLQHreceived  <0.0001   <0.0001 
 0 1 (reference)   1 (reference)  
 1 0.45 (0.240.84)   1.15 (0.542.33)  
 2 0.39 (0.23   0.46 (0.210.94)  
 3    0.45 (0.290.68)  
6,0'TXLQWLOH  0.0322   0.0028 
 1 (most deprived) 1 (reference)   1 (reference)  
 2 01.02)   1.05 (0.821.33)  
 3 01.03)   1.19)  
 4 1.11)   0.94)  
 5 (least deprived) 0.92)   0.99)  
Age at vaccination, y§   <0.0001    
 1516 1 (reference)   1 (reference)  
  1.33 (0.921.91)   1.26 (0.801.98)  
 18 2.53)   2.08)  
 >18 3.41 (1.985.82)   1.50 (0.683.12)  
+39KXPDQSDSLOORPDYLUXV25RGGVUDWLR; SIMD, 6FRWWLVK,QGH[RI0XOWLSOH'HSULYDWLRQ. 
+39types 31, 33, or 45. 





higher among nonvaccinated women in 2010, 2011, and 
 25 >&,±@25 >±









W\SHV  DQG  DPRQJ ZRPHQ LQ 6FRWODQG DVVRFLDWHG
ZLWK KLJK UDWHV RI YDFFLQDWLRQ ZLWK WKH ELYDOHQW +39
vaccine. There is evidence that each dose administered 
FRQIHUUHGSURWHFWLRQDJDLQVW+39W\SHRUDQGWKDW
WKH RGGV RI LQIHFWLRQ ZHUH VLJQL¿FDQWO\ UHGXFHG DIWHU 
DQGGRVHV2XU¿QGLQJVDUHFRPSDUDEOHZLWK WKRVHRI
a nested analysis of a randomized controlled trial, which 
UHSRUWHGHI¿FDF\RIDQGGRVHVRIELYDOHQW+39YDF-
FLQHDJDLQVW+39DQGLQIHFWLRQ17). However, be-
cause of the small number of women in our study who had 
received 2 doses and because our study was powered to 
GHWHFWDQHIIHFWRIGRVHVWKH¿QGLQJVZLWKUHJDUGWRHI-
fectiveness of <3 doses should be considered preliminary 
and may be confounded by other factors. Our evidence 
RI WKH YDFFLQH FRQIHUULQJ FURVVSURWHFWLRQ DJDLQVW +39
W\SHVDQGLVDOVRFRQVLVWHQWZLWK¿QGLQJVRID
previous study (18). Of note, published results of a recent 
study in England (6) do not report similar reductions in 
FURVVSURWHFWLYHW\SHVKRZHYHUWKHDXWKRUVRIWKDWDUWLFOH
concluded that further analysis of samples from women in 
birth cohorts with high vaccine coverage was needed for 
full evaluation of the effects of vaccination on prevalence 
RIQRQYDFFLQH+39W\SHV
:HREVHUYHGD UHGXFWLRQ LQ WKHSUHYDOHQFHRI+39
W\SHVDQGDPRQJQRQYDFFLQDWHGZRPHQXQGHUJRLQJ
WKHLU¿UVWFHUYLFDOVPHDU WHVWLQJ LQ7KLV¿QGLQJ LV
encouraging evidence of herd immunity and corroborates 
WKH¿QGLQJVRIVWXGLHV IURP$XVWUDOLDDVH[XDOKHDOWK
clinicbased national surveillance study that observed 
a decline in genital warts among heterosexual men and 
D FURVVVHFWLRQDO VWXG\ WKDW VKRZHG D GHFUHDVH LQ +39
prevalence among nonvaccinated women (12,13). These 
data and our data are welcome because protecting the 
QRQYDFFLQDWHGSRSXODWLRQIURPLQIHFWLRQZLWK+39RU
18 depends on development of herd immunity. However, 
the limited number of nonvaccinated women, particularly 
in later years since the introduction of the program, makes 
interpretation of these results somewhat challenging, as 
UHÀHFWHG LQ WKH&,V ,QDGGLWLRQ DOWKRXJK LQQRQ-
vaccinated women were not vaccinated because of in-
eligibility, in 2013, nonvaccinated women may not have 















(95% CI) 1RSRV 3RV&, 
8QDGMXVWHG25
(95% CI) 
Collection year         
 2009 1,652 480 29.1 (26.931.3) 1 (reference)  959 60.4) 1 (reference) 
 2010 1,053 364  1.29 (1.091.52)  618 61.6) 1.01 (0.861.18) 
 2011 1,001 330 33.0 (30.135.9) 1.20 (1.011.42)   58.6 (55.6 1.05 (0.891.23) 
 2012 993 352 35.5 (32.538.4) 1.34 (1.131.59)  580 58.4 (55.361.4) 1.04 (0.881.21) 
 2013 1,016 344 33.9 (31.036.8) 1.25 (1.061.48)   53.8 (50.856.8) 1.02) 
1RGRVHV         
 0 3,619  32.5 (31.034.0) 1 (reference)  2162 61.3) 1 (reference) 
 1 89 32 36.0 (26.846.3) 1.80)  55 61.8 (51.4  
 2 154 53 42.2) 1.52)  91 59.0 (51.266.5) 1.40) 
 3 1,853 609 32.9 (30.835.0) 1.02 (0.901.15)  983 55.3)  
Birth year         
 1988 844 235 31.0) 1 (reference)   56.5 (53.259.8) 1 (reference) 
 1989 1,196  31.0 (28.5 1.18 (0.981.44)   61.3) 1.09 (0.911.30) 
 1990 1,204 413  1.66)   60.6) 1.06 (0.891.26) 
 1991   33.1 (30.136.3) 1.28 (1.041.58)  515 59.4 (56.162.6) 1.13 (0.931.36) 
 1992 1,261 435 34.5 (31.9 1.36 (1.121.64)   56.0 (53.2 0.98 (0.82 
 1993 393 129 32.8 (28.4 1.62)  196 49.9 (45.054.8) (0.60 
Age at vaccination, y         
 1516  305 31.4 (28.634.4) 1 (reference)  491 53.8) 1 (reference) 
  631 241 38.2 (34.542.0) 1.34 (1.091.66)  358 60.5) 1.28 (1.05 
 18 391 116 34.4) 0.92 1.19)  220 56.3 (51.361.1) 1.26 (0.991.59) 
 >18 109 32 29.4 (21.638.5) 0.93 (0.591.42)  60 64.1) 1.19 (0.80 






VRFLHWDO ZKLFK PD\ LQÀXHQFH WKHLU OLNHOLKRRG RI EHLQJ
LQIHFWHGE\+39W\SHVRUUHODWLYHWRZRPHQLQWKH
2009 cohort. However, the increased odds of infection 
ZLWK QRQYDFFLQH QRQ±FURVVSURWHFWLYH KLJKULVN +39
W\SHVDQGDQ\+39W\SHDPRQJQRQYDFFLQDWHGZRPHQLQ
years after 2009 suggests that these reasons are probably 
not a major confounding factor. Data from future cohorts 
will show whether the reduction of infection among non-
vaccinated women is sustained.
It has been postulated that the reduction of infection 
ZLWK+39W\SHVDQGDQGFURVVSURWHFWLYHW\SHVFRXOG
leave a vacant niche, leading to increased infections with 
OHVV RQFRJHQLF QRQYDFFLQH +39 W\SHV DPRQJ YDFFLQDWHG
women (19,20). We found that odds of infection with non-
YDFFLQH QRQ±FURVVSURWHFWLYH KLJKULVN +39 W\SHV ZHUH
higher among women in later birth cohorts than among 
those in earlier birth cohorts. Furthermore, we observed that 
the most common high-risk type infecting fully vaccinated 
ZRPHQLQODWHUFRKRUWVZDV+39UHSODFLQJ+39DV
the most prevalent type but at lower rates. However, because 
of the increased overall prevalence between 2009 and 2013, 
FRPSDULVRQ RI QRQYDFFLQH KLJKULVN +39 W\SH SUHYDOHQFH
between nonvaccinated and fully vaccinated women will 
be confounded. It is feasible that rather than truly replac-
ing vaccine types, the other high-risk types are simply be-
ing unmasked because of less competition for the resources 
ZLWKLQ PROHFXODU DPSOL¿FDWLRQ DVVD\V 21 &RQVHTXHQWO\
we found no strong evidence for type replacement occurring 
LQ6FRWODQGWKHVHUHVXOWVDUHFRQVLVWHQWZLWKGDWDIURP$XV-
tralia (22&RQWLQXHGIROORZXSLVQHHGHGIRUHYDOXDWLRQRI
the potential for type replacement after high uptake of the 
ELYDOHQW+39YDFFLQH2XURQJRLQJDQDO\VLVRI+39SUHYD-
OHQFHDPRQJZRPHQZLWKKLVWRORJLFDOO\FRQ¿UPHGFHUYLFDO
lesions and linkage to colposcopy data to assess cervical dis-
ease in the female population of Scotland will aid in address-




Table 5. Adjusted odds of positivity for high-ULVN+39H[FOXGLQJYDFFLQHDQGFURVV-SURWHFWLYHW\SHVDQGDQ\+39W\SHE\ELUWK\HDU






$GMXVWHG25&, /LQHDUWUHQGSYDOXH $GMXVWHG25&, /LQHDUWUHQGSYDOXH 
Birth year     0.1158 
 1988 1 (reference)   1 (reference)  
 1989 1.44)   1.08 (0.911.29)  
 1990 1.41 (1.16   1.10 (0.921.32)  
 1991 1.32 (1.041.69)   1.36 (1.08  
 1992 1.49 (1.161.91)   1.39 (1.10  
 1993 1.46 (1.062.00)   1.13 (0.841.53)  
1RGRVHVYDFFLQHUHFHLYHG  0.2953   0.004 
 0 1 (reference)   1 (reference)  
 1 0.89 (0.531.48)   1.30)  
 2 0.84 (0.56     
 3 0.80 (0.631.02)   0.60 (0.48  
6,0'TXLQWLOH     0.0002 
 1 (most deprived) 1 (reference)   1 (reference)  
 2 0.99 (0.84   0.93 (0.801.10)  
 3 0.99 (0.841.18)     
 4 0.98 (0.82   1.03)  
 5 (least deprived) 1.03)   0.86)  
Age at vaccination, y§   0.4541   0.331 
 1516 1 (reference)   1 (reference)  
  1.40 (1.10   1.2 (0.951.51)  
 18 1.35)   1.24 (0.921.68)  
 >18 0.98 (0.60   1.25 (0.801.96)  
*+39KXPDQSDSLOORPDYLUXV25RGGVUDWLR6,0'6FRWWLVK,QGH[RI0XOWLSOH'HSULYDWLRQ 
+39RU 






Table 6. 3UHYDOHQFHDQGRGGVRILQIHFWLRQZLWK+39 W\SHVRUDQGIRU+39FURVV-protective types among QRQYDFFLQDWHGZRPHQ






1RSRV 3RV&, 25&, 1RSRV 3RV&, 25&, 
2009 1,652 468 28.3 (26.2±30.6) 1 (reference)  211 12.8 (11.2±14.5) 1 (reference) 
2010 1,012 310 ±33.5) 1.13 (0.95±1.34)  139 ±16.0) ±1.38) 
2011  164 29.4 (25.8±33.4) 1.05 (0.85±1.29)   ±15.8) ±1.32) 
2012 245  31.8 (26.3± 1.18 (0.88±  28 11.4 (8.0±16.0) 0.88 (0.58±1.33) 






The main strength of this study is that vaccination and 
VFUHHQLQJGDWDFDQEHOLQNHGDWWKHLQGLYLGXDOOHYHO&RXSOHG
with the high levels of vaccine uptake and age of screening 
in Scotland, this linkage enables us to directly evaluate the 
HIIHFWVRI+39YDFFLQDWLRQRQ+39SUHYDOHQFH
Nevertheless, our study has some limitations. Data 
from a screened population are not representative of the 
whole population and possibly underestimate the true 
SUHYDOHQFH RI +39 LQIHFWLRQ +RZHYHU WKH SUHYDOHQFH
RI+39DPRQJ\HDUROGZRPHQZKRGLGQRWXQGHUJR
a cervical screening test but were invited to send a self-
collected urine sample or vaginal swab sample did not dif-
IHU VLJQL¿FDQWO\ IURP SUHYDOHQFH DPRQJ WKRVH ZKR KDG
undergone cervical screening testing in a previous study 
(23). We were also unable to collect sexual history data 
and so could not determine an overall change in sexual 
practices among the population, which might confound 
our results. However, our observed increase in prevalence 
RIQRQYDFFLQHQRQ±FURVVSURWHFWLYHKLJKULVN+39W\SHV
among vaccinated and nonvaccinated women and the rel-
DWLYHVWDELOLW\RIWKHSUHYDOHQFHRI+39RYHUDOOVXJJHVWV
either an increase or stabilization of sexual behavior be-
tween 2009 and 2013. Also, the results of the third Na-
tional Surveys of Sexual Attitudes and Lifestyles study, 
conducted in 2013, showed that the number of womens 
OLIHWLPHVH[SDUWQHUVDNQRZQULVNIDFWRUIRU+39LQIHF-
tion, has increased since 2000, and it is therefore more 
likely that the effect of the vaccine has been underestimat-
ed in our study (24). In addition, the incidence of genital 
KHUSHVDQGJRQRUUKHDLQ6FRWODQGLQFUHDVHGIURPWR
2014, suggesting that sexual activity has increased over 
time (25). However, women in later birth cohorts within 
the catch-up campaign are more likely to have received 
the vaccine within the school-based program than were 
those in earlier birth cohorts, who are more likely to have 
received the vaccine out of school (in general practice). 
3UHYLRXVVWXGLHVKDYHVKRZQWKDWWKRVHZKROHDYHVFKRRO
are more likely to be from high-deprivation backgrounds 
DQGDUHFRQVHTXHQWO\PRUHOLNHO\WREHLQIHFWHGZLWK+39
(4,26 7KHUHIRUH WKH HIIHFW RI WKH +39 YDFFLQH PD\
be confounded by differences between those who leave 
school and those who stay in school.
Our data preliminarily suggest the presence of herd 
immunity in the nonvaccinated female population of 
Scotland. However, we could not assess whether herd im-
munity is conferring protection to the male population, 
who are not routinely sampled as part of the surveillance 
program. We plan to use genital wart consultation data 
from men to act as a proxy for detecting herd immunity in 
the male population (13,QWKHPHDQWLPHWKH¿UVWJLUOV
who received the vaccine as part of the routine vaccination 




naive, women in Scotland.
0RQLWRULQJDQGHYDOXDWLRQRIWKH+39LPPXQL]DWLRQSURJUDPLQ
Scotland is funded by the Scottish government.
0U&DPHURQLVDQHSLGHPLRORJLVWDW+HDOWK3URWHFWLRQ6FRWODQG
Glasgow. His research interest is the epidemiology of infectious 




































and cross-protective types 
 
$Q\+39 
1RSRV 3RV&, 25&, 1RSRV 3RV&, 25&, 
2009 1.652  28.6 (26.530.9) 1  946 59.6) 1 
2010 1,012 338 33.4 (30.636.4) 1.5)   60.1) 0.99 (0.851.16) 
2011  210 41.8) 1.50 (1.221.83)  354 59.5 (59.5 1.59) 
2012 245 90 42.9) 1.44 (1.091.91)  166  1.56 (1.182.09) 
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